{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:14:21Z","timestamp":1791288861122,"version":"4.3.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12325-024-02975-x","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T12:02:20Z","timestamp":1726056140000},"page":"4125-4139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"Ana","family":"Oaknin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-1350","authenticated-orcid":false,"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-7614","authenticated-orcid":false,"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-9901","authenticated-orcid":false,"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-7934","authenticated-orcid":false,"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-9576","authenticated-orcid":false,"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7224","authenticated-orcid":false,"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-178X","authenticated-orcid":false,"given":"Iwona","family":"\u0141ugowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6182-1115","authenticated-orcid":false,"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-1801","authenticated-orcid":false,"given":"Ar\u00e1nzazu","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5474-6866","authenticated-orcid":false,"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-2846","authenticated-orcid":false,"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-1092","authenticated-orcid":false,"given":"Daniil","family":"Stroyakovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitra","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-1824","authenticated-orcid":false,"given":"Soham","family":"Puvvada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"20","key":"2975_CR1","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"2975_CR2","unstructured":"U.S. Food and Drug Administration (FDA). ENHERTU (fam-trastuzumab deruxtecan-nxki): highlights of prescribing information. 2024. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761139s028lbl.pdf. Accessed Jun 21, 2024."},{"key":"2975_CR3","unstructured":"Daiichi Sankyo. Press release. ENHERTU\u00ae approved in Japan as first HER2 directed therapy for patients with HER2 mutant metastatic non-small cell lung cancer. 2023. Available from: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202308\/20230823_E.pdf. Accessed Jun 21, 2024."},{"key":"2975_CR4","unstructured":"European Medicines Agency (EMA). ENHERTU: summary of product characteristics. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enhertu-epar-product-information_en.pdf. Accessed Jun 21, 2024."},{"key":"2975_CR5","unstructured":"AstraZeneca. Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours. 2024. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours.html. Accessed Jun 21, 2024."},{"issue":"1","key":"2975_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2975_CR7","first-page":"704","volume":"18","author":"KAB Goddard","year":"2012","unstructured":"Goddard KAB, Bowles EJA, Feigelson HS, et al. Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care. 2012;18(11):704\u201312.","journal-title":"Am J Manag Care"},{"issue":"10","key":"2975_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.5858\/arpa.2022-0229-CP","volume":"147","author":"IS Hagemann","year":"2023","unstructured":"Hagemann IS, Bridge JA, Tafe LJ, et al. Current laboratory testing practices for assessment of ERBB2\/HER2 in endometrial serous carcinoma and colorectal carcinoma. Arch Pathol Lab Med. 2023;147(10):1148\u201357.","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"2975_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","volume":"140","author":"AN Bartley","year":"2016","unstructured":"Bartley AN, Washington MK, Ventura CB, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345\u201363.","journal-title":"Arch Pathol Lab Med"},{"key":"2975_CR10","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Trastuzumab deruxtecan for pretreated patients with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 study. Oral presentation at the 2023 European Society for Medical Oncology Annual Meeting, Madrid, Spain, Sep 13\u201317, 2023 (Abstract #1568).","DOI":"10.1016\/j.annonc.2023.10.026"},{"issue":"11","key":"2975_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","volume":"34","author":"B Uzunparmak","year":"2023","unstructured":"Uzunparmak B, Haymaker C, Raso G, et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol. 2023;34(11):1035\u201346.","journal-title":"Ann Oncol"},{"issue":"10","key":"2975_CR12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","volume":"25","author":"C Vivaldi","year":"2020","unstructured":"Vivaldi C, Fornaro L, Ugolini C, et al. HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. Oncologist. 2020;25(10):886\u201393.","journal-title":"Oncologist"},{"issue":"2","key":"2975_CR13","first-page":"42","volume":"7","author":"I Roa","year":"2014","unstructured":"Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res. 2014;7(2):42\u20138.","journal-title":"Gastrointest Cancer Res"},{"issue":"2","key":"2975_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","volume":"60","author":"A Fleischmann","year":"2011","unstructured":"Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. HER2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60(2):350\u20137.","journal-title":"Eur Urol"},{"issue":"7","key":"2975_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1464-410X.2005.05452.x","volume":"95","author":"T G\u00e5rdmark","year":"2005","unstructured":"G\u00e5rdmark T, Wester K, De La Torre M, Carlsson J, Malmstr\u00f6m P-U. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 2005;95(7):982\u20136.","journal-title":"BJU Int"},{"issue":"8","key":"2975_CR16","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","volume":"31","author":"A Moktefi","year":"2018","unstructured":"Moktefi A, Pouessel D, Liu J, et al. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Mod Pathol. 2018;31(8):1270\u201381.","journal-title":"Mod Pathol"},{"issue":"1","key":"2975_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cjp2.184","volume":"7","author":"H Shi","year":"2021","unstructured":"Shi H, Shao Y, Lu W, Lu B. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification. J Pathol Clin Res. 2021;7(1):86\u201395.","journal-title":"J Pathol Clin Res"},{"issue":"3","key":"2975_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/bjc.2017.422","volume":"118","author":"MK Halle","year":"2018","unstructured":"Halle MK, Tangen IL, Berg HF, et al. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. Br J Cancer. 2018;118(3):378\u201387.","journal-title":"Br J Cancer"},{"issue":"11","key":"2975_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001138","volume":"2","author":"M Tuefferd","year":"2007","unstructured":"Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE. 2007;2(11):e1138.","journal-title":"PLoS ONE"},{"issue":"8","key":"2975_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/gm482","volume":"5","author":"A Chou","year":"2013","unstructured":"Chou A, Waddell N, Cowley MJ, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013;5(8):78.","journal-title":"Genome Med"},{"issue":"4","key":"2975_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/diagnostics11040653","volume":"11","author":"S-H Han","year":"2021","unstructured":"Han S-H, Ryu KH, Kwon A-Y. The prognostic impact of HER2 genetic and protein expression in pancreatic carcinoma-HER2 protein and gene in pancreatic cancer. Diagnostics (Basel). 2021;11(4):653.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"2975_CR22","first-page":"55","volume":"39","author":"H Semiz","year":"2023","unstructured":"Semiz H, Pala E, Can B, Atag E, Gungor H, Sanci M. cERBB-2\/Her-2 Neu overexpression and prognostic significance in uterine carcinosarcoma. Turk Patoloji Derg. 2023;39(1):55\u201363.","journal-title":"Turk Patoloji Derg"},{"issue":"4","key":"2975_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/his.14381","volume":"79","author":"L Vermij","year":"2021","unstructured":"Vermij L, Singh N, Leon-Castillo A, et al. Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. Histopathology. 2021;79(4):533\u201343.","journal-title":"Histopathology"},{"issue":"12","key":"2975_CR24","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","volume":"26","author":"N Buza","year":"2013","unstructured":"Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol. 2013;26(12):1605\u201312.","journal-title":"Mod Pathol"},{"issue":"5","key":"2975_CR25","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e75","volume":"30","author":"YW Chung","year":"2019","unstructured":"Chung YW, Kim S, Hong JH, et al. Overexpression of HER2\/HER3 and clinical feature of ovarian cancer. J Gynecol Oncol. 2019;30(5):e75.","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"2975_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/PGP.0000000000000812","volume":"41","author":"E Ersoy","year":"2022","unstructured":"Ersoy E, Cao QJ, Otis CN. HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas. Int J Gynecol Pathol. 2022;41(4):313\u20139.","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"2975_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/sj.bjc.6603581","volume":"96","author":"D Pils","year":"2007","unstructured":"Pils D, Pinter A, Reibenwein J, et al. In ovarian cancer the prognostic influence of HER2\/neu is not dependent on the CXCR4\/SDF-1 signalling pathway. Br J Cancer. 2007;96(3):485\u201391.","journal-title":"Br J Cancer"},{"issue":"4","key":"2975_CR28","first-page":"218","volume":"5","author":"G Panek","year":"2007","unstructured":"Panek G, Ligaj M. Prognostic significance of HER-2\/neu expression in patients at early clinical stages of invasive cervical cancer. Gin Onkol. 2007;5(4):218\u201335.","journal-title":"Gin Onkol"},{"key":"2975_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014: 852748.","journal-title":"Mol Biol Int"},{"issue":"13","key":"2975_CR30","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2975_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2975_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437\u201348.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"2975_CR33","doi-asserted-by":"publisher","first-page":"S782","DOI":"10.1016\/j.annonc.2022.07.648","volume":"33","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Moore KN, Meyer T, et al. Safety and efficacy of nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients (pts) with recurrent\/metastatic cervical cancer (R\/M Cx Ca) in CheckMate 358. Ann Oncol. 2022;33(Suppl):S782 (Abstract 520MO).","journal-title":"Ann Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02975-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02975-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02975-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T02:02:44Z","timestamp":1741226564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02975-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2975"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02975-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana Oaknin has received consulting fees from Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo, Debiopharm, Deciphera Pharmaceuticals, Eisai, Exelisis, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana Therapeutics, Myriad Genetics, Novocure, OncXerna Therapeutics, Pfizer, PharmaMar, Regeneron Pharmaceuticals, Roche, Shattuck Labs, Sutro Biopharma, and Zentalis Pharmaceuticals; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Asociaci\u00f3n Colombiana de Ginecol\u00f3gos Onc\u00f3logos, AstraZeneca, European School of Oncology, GSK, Medscape, NSGO, PeerView, and PeerVoice; support for attending meetings and\/or travel from AstraZeneca, PharmaMar, and Roche; participated on a Data Safety Monitoring Board or Advisory Board for Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo, Debiopharm, Deciphera Pharmaceuticals, Eisai, Exelisis, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana Therapeutics, Myriad Genetics, Novocure, OncXerna Therapeutics, Pfizer, PharmaMar, Regeneron Pharmaceuticals, Roche, Shattuck Labs, Sutro Biopharma, and Zentalis Pharmaceuticals; and held a leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, for the European Society for Medical Oncology, as European Society for Medical Oncology Guidelines Gynecology Subject Editor, as European Society for Medical Oncology Gynecology Meeting Chair, as European Society for Medical Oncology Gynecology Faculty Member, for the Gynecologic Cancer Intergroup, and as Gynecologic Cancer Intergroup Cervical Cancer Committee Chair. Jung-Yun Lee has participated on a Data Safety Monitoring Board or Advisory Board for Eisai and GI Innovation Inc.; and has other financial or non-financial interests with Alkermes, AstraZeneca, BeiGene, BerGenBio, Cellid, Clovis Oncology, Eisai, GI Innovation, ImmunoGen, Janssen, Merck, Mersana Therapeutics, MSD, Novartis, OncoQuest Pharmaceuticals, ONO Pharmaceutical Co., Ltd., Roche, Seagen, Synthon, and Takeda Pharmaceuticals. Vicky Makker has received grants or contracts from AstraZeneca, Bristol-Myers Squibb, Clasi, Cullinan Therapeutics, Duality Biologics, Eisai, Faeth Therapeutics, Karyopharm Therapeutics, Merck, Takeda Pharmaceuticals, and Zymeworks; support for attending meetings and\/or travel from Eisai, Karyopharm Therapeutics, and Merck; and has other financial or non-financial interests with Clovis, Cullinan Therapeutics, Duality Biologics, Eisai, Faeth Therapeutics, GSK, Immunocore, iTeos Therapeutics, Karyopharm Therapeutics, Lilly, Merck, Mereo BioPharma, MorphoSys, MSD, Novartis, Regeneron Pharmaceuticals, Sutro Biopharma, and Zymeworks. Do-Youn Oh has received grants or contracts from Array BioPharma, AstraZeneca, BeiGene, Eli Lilly and Company, HANDOK, MSD, Novartis, and Servier; and has participated on a Data Safety Monitoring Board or Advisory Board for Arcus Biosciences, ASLAN Pharmaceuticals, AstraZeneca, Basilea, Bayer, BeiGene, Bristol-Myers Squibb, Genentech\/Roche, Halozyme, IQVIA, Merck, MSD, Novartis, Taiho Pharmaceutical Co., Ltd., Turning Point Therapeutics, Yuhan Corporation, and Zymeworks. Susanna Banerjee has received grants or contracts from AstraZeneca and GSK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, Clovis Oncology, GSK, ImmunoGen, Medscape, Merck, Mersana Therapeutics, Novocure, Pfizer, Research to Practice, Roche, and Takeda Pharmaceuticals; support for attending meetings and\/or travel from GSK and Verastem Oncology; participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Epsilogen, GSK, ImmunoGen, Merck, Mersana Therapeutics, Novartis, OncXerna Therapeutics, Seagen, Shattuck Labs, Regeneron Pharmaceuticals, and Verastem Oncology; held a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with the International Cancer Foundation; and has stock or stock options with Perci Health. Antonio Gonz\u00e1lez-Mart\u00edn has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Clovis Oncology, GSK, Novocure, MSD, Roche, Takeda Pharmaceuticals, and Zai Lab; support for attending meetings and\/or travel from AstraZeneca, GSK, and MSD; participated on a Data Safety Monitoring Board or Advisory Board for Alkermes, Amgen, AstraZeneca, BioNTech, Clovis Oncology, Daiichi Sankyo, Eisai, Genmab, GSK, Hedera Dx, Illumina, ImmunoGen, Incyte Corporation, Kartos Therapeutics, MacroGenics, Mersana Therapeutics, MSD, Novartis, Novocure, Oncoinvent, PharmaMar, Regeneron Pharmaceuticals, Roche, Sutro Biopharma, SOTIO Biotech, and Tubulis; and has other financial or non-financial interests with GSK and Roche. Kyung Hae Jung has received consulting fees from AstraZeneca, BIXINK, Celgene, Daiichi Sankyo, Eisai, Everest Medicines, Gilead Sciences, MSD, Novartis, Pfizer, Roche, and Takeda Pharmaceuticals. Iwona \u0141ugowska has received grants or contracts from Agenus and Roche; and has other financial or non-financial interests with Agenus, AstraZeneca, Amgen, Bristol-Myers Squibb, Celon Pharma SA, CliniNote, the European Society for Medical Oncology, Incyte, Janssen, Menarini, MSCI, MSD, the Organisation of European Cancer Institutes, Pfizer, Rhizen, Roche, Ryvu Therapeutics, and Sairopa. Luis Manso declares no conflicts of interest. Ar\u00e1nzazu Manzano has received grants or contracts from AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, GSK, LEO Pharma, MSD, PharmaMar, and Sanofi; support for attending meetings and\/or travel from AstraZeneca, GSK, and MSD; and participated on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, GSK, and PharmaMar. Bohuslav Melichar has received consulting fees from AstraZeneca, Amgen, Bristol-Myers Squibb, Lilly, Merck, MSD, Novartis, Pfizer, Roche, and Servier; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Amgen, Bristol-Myers Squibb, EMD Serono, Lilly, Merck, MSD, Novartis, Pfizer, Roche, and Servier; support for attending meetings and\/or travel from AstraZeneca, Bristol-Myers Squibb, Merck, and MSD; and has participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, MSD, Novartis, Pfizer, and Roche. Salvatore Siena has participated on a Data Safety Monitoring Board or Advisory Board for Agenus, AstraZeneca, Bristol-Myers Squibb, Checkmab, Daiichi Sankyo, GSK, MSD, Novartis, Seagen, and T-ONE Therapeutics. Daniil Stroyakovskiy declares no conflicts of interest. Anitra Fielding holds stock or stock options with AstraZeneca and discloses other financial or non-financial interests with AstraZeneca (employment). Soham Puvvada holds stock or stock options with AstraZeneca and discloses other financial or non-financial interests with AstraZeneca (employment). Ann Smith holds stock or stock options with AstraZeneca and discloses other financial or non-financial interests with AstraZeneca (employment). Funda Meric-Bernstam has received grants or contracts from Aileron Therapeutics, AstraZeneca, Bayer, Calithera Biosciences, Curis, Inc., CytomX Therapeutics, Daiichi Sankyo, Debiopharm, eFFECTOR Therapeutics, Genentech Inc., Guardant Health, KLUS Pharma, Novartis, Puma Biotechnology, Takeda Pharmaceuticals, and Taiho Pharmaceutical Co., Ltd.; consulting fees from AbbVie, AstraZeneca, BD, Calibr-Skaggs at Scripps Research, Daiichi Sankyo, EcoR1 Capital, eFFECTOR Therapeutics, Exelixis, GT Apeiron, Incyte, Infinity Pharmaceuticals, Jazz Pharmaceuticals, LegoChem Biosciences, Lengo Therapeutics, Menarini, Molecular Templates, Protai, Roche, Tallac Therapeutics, and Zymeworks; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from DAVA Oncology; received support for attending meetings and\/or travel from the Cholangiocarcinoma Foundation, the European Organisation for Research and Treatment of Cancer, the European Society for Medical Oncology, and DAVA Oncology; and participated on a Data Safety Monitoring Board or Advisory Board for Black Diamond Therapeutics, Biovica International AB, Eisai, FogPharma, Harbinger Health, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Sanofi, Seagen, Theratechnologies, and Zentalis Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All patients provided written informed consent. The study was approved by independent institutional review boards of each participating site and was conducted in accordance with the ethics principles of the Declaration of Helsinki and with Good Clinical Practice guidelines defined by the International Conference on\u00a0Harmonisation. A list of these individual review boards has been provided as a supplementary appendix.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}